TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06313502

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 75gm HDAA
Description: Initiation: Subjects will receive a test dose of ascorbate (15 gm), during screening period, prior to starting therapy.~Dose: After successfully completing the test dose, subjects will receive 75gm of ascorbate infusion. Dose modifications will not be made for weight or body surface area.~Administration: Infusion time is set to occur at 120 minutes +/-10 minutes but may be adjusted for subject comfort. The infusion rate should not exceed 500 mL/hour without consulting with PI. Changes in infusion rates should be recorded.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 100gm HDAA
Description: Initiation: Subjects will receive a test dose of ascorbate (15 gm), during screening period, prior to starting therapy.~Dose: After successfully completing the test dose, subjects will receive 100gm of ascorbate infusion. Dose modifications will not be made for weight or body surface area.~Administration: Infusion time is set to occur at 180 minutes +/-10 minutes but may be adjusted for subject comfort. The infusion rate should not exceed 500 mL/hour without consulting with PI. Changes in infusion rates should be recorded.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 125gm HDAA
Description: Initiation: Subjects will receive a test dose of ascorbate (15 gm), during screening period, prior to starting therapy.~Dose: After successfully completing the test dose, subjects will receive 125gm of ascorbate infusion. Dose modifications will not be made for weight or body surface area.~Administration: Infusion time is set to occur at 240 minutes +/-10 minutes but may be adjusted for subject comfort. The infusion rate should not exceed 500 mL/hour without consulting with PI. Changes in infusion rates should be recorded.
Study: NCT06243003

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: HA-WBRT plus SBRT
Description: hippocampal-avoidance whole brain radiotherapy (WBRT) followed by stereotactic body radiotherapy (SBRT)
Study: NCT05259137

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intralesional enalaprilat injection
Description: 1.0 mL of 1.25 mg/mL enalaprilat
Study: NCT00754949

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 1% Azithromycin and 0.1% Dexamethasone
Description: Subjects will dose topically to the eye and eyelid BID at approximately 12 hour intervals for 14 days in both eyes.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 1% Azithromycin
Description: Subjects will dose topically to the eye and eyelid BID at approximately 12 hour intervals for 14 days in both eyes.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 0.1% Dexamethasone
Description: Subjects will dose topically to the eye and eyelid BID at approximately 12 hour intervals for 14 days in both eyes.
Study: NCT05287841

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Batten batten graft
Description: The batten grafts are autologous grafts from the patients' own tissue, produced from nasal septal quadrangular cartilage. This will be obtained during the septoplasty portion of the procedure. The batten graft will be used to stabilize the internal nasal valve and prevent nasal valve collapse on inspiration.
Study: NCT06268015

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Panitumumab
Description: 6 mg/kg IV every 2 weeks
Study: NCT05935046

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Walk test and meal test
Description: The subjects will perform a treadmill walking test at increasing speed from 2 to 6km.h-1 in 5min increments.~During the second experimental visit, subjects will be required to consume a test meal containing 590kcal (12% protein, 35% fat, 53% carbohydrate) (Duhita et al 2017).~The composition of the test meal will be developed based on the food preferences and habits questionnaires completed during the inclusion visit. Foods indicated as preferred by participants will not be offered during these sessions to avoid any influence of their palatable nature on participants' consumption.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Walk test and meal test
Description: The subjects will perform a treadmill walking test at increasing speed from 2 to 6km.h-1 in 5min increments.~During the second experimental visit, subjects will be required to consume a test meal containing 590kcal (12% protein, 35% fat, 53% carbohydrate) (Duhita et al 2017).~The composition of the test meal will be developed based on the food preferences and habits questionnaires completed during the inclusion visit. Foods indicated as preferred by participants will not be offered during these sessions to avoid any influence of their palatable nature on participants' consumption.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Walk test and meal test
Description: The subjects will perform a treadmill walking test at increasing speed from 2 to 6km.h-1 in 5min increments.~During the second experimental visit, subjects will be required to consume a test meal containing 590kcal (12% protein, 35% fat, 53% carbohydrate) (Duhita et al 2017).~The composition of the test meal will be developed based on the food preferences and habits questionnaires completed during the inclusion visit. Foods indicated as preferred by participants will not be offered during these sessions to avoid any influence of their palatable nature on participants' consumption.
Study: NCT06690138

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Itraconazole
Description: Itraconazole will be administered BID on Day 1 and QD from Day 2 to 13 and as specified for the respective period.
Study: NCT06690281

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: KRAS TCR-Transduced PBL
Description: Day 0: Cells will be infused intravenously (IV) over 20-30 minutes (2-4 days after the last dose of fludarabine)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aldesleukin
Description: Aldesleukin 600,000 IU/kg IV (based on total body weight) over 15 minutes approximately every 8 hours beginning within 24 hours of cell infusion and continuing for up to 3 days (maximum 3 doses)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Days -7 to -3: Fludarabine 25 mg/m\^2/day IVPB daily over 30 minutes for 4 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Days -7 and -6: Cyclophosphamide 30 mg/kg/day x 2 days IV in 250 mL D5W infused simultaneously with mesna 7.5 mg/kg/day over 1 hour x 2 days
Study: NCT06688396

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Mobile 6L AI-EKG Screening
Description: Participants (probands) with DCM will invite their first-degree relatives to undergo DCM screening procedures.~Probands and first-degree relatives will complete a mobile 6L AI-EKG which will be transmitted to a mobile app and interpreted by the AI-EKG algorithm. Results will be shared electronically or verbally to the participant.~If available, the probands clinical 12L EKGs will be obtained if recorded within 30 days of their Kardia 6L recording.~All participating FDR will be encouraged to pursue cardiac screening per ACC/AHA recommendations. Study staff will obtain echocardiogram results up to 6 months of participant enrollment.
Study: NCT06691256

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: HiDO-ALZ
Description: HiDO-ALZ platform, an AI-driven medication dispensing and observation system designed to improve adherence in individuals with dementia and diabetes.
Study: NCT05628363

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ethos Varian treatment system
Description: Device that will be used to administer radiotherapy

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Adaptive stereotactic body radiotherapy
Description: Radiotherapy interruptions are acceptable as long as treatments are no more than 16 days apart.
Study: NCT05287841

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Septoplasty
Description: A portion of the quadrangular cartilage of the nasal septum is removed. This will be performed as a standard septoplasty.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Septoplasty
Description: A portion of the quadrangular cartilage of the nasal septum is removed. This will be performed as a standard septoplasty.
Study: NCT05628363

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Androgen deprivation therapy
Description: Androgen deprivation therapy (ADT) will be administered to study patients according to institutional standard. Patients should initiate ADT beginning no sooner than 60 days prior to start of radiation. ADT is defined as a GnRH agonist/antagonist (leuprolide, goserelin, degarelix, or relugolix). Patients treated with leuprolide, goserelin, or degarelix should also receive an androgen receptor antagonist (flutamide or bicalutamide) for 30 days from the start of GnRH agonist/antagonist or until the end of radiation, depending on institutional standard and physician preference.~Agent selection is per treating physician discretion and will be administered per institutional standard and FDA-approved labeling.
Study: NCT06224855

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DXC006
Description: Dose escalation period: DXC006 is administered intravenously every two weeks (Q2W) at the dose corresponding to the enrolled dose cohort.~Dose expansion period: DXC006 is administered intravenously Q2W at the corresponding dose.
Study: NCT04821739

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AGN1 LOEP SV Kit
Description: The AGN1 LOEP SV Kit is intended for fixation of pathological fractures of the vertebral body using vertebral augmentation.
Study: NCT06696677

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: CT
Description: CT measurment of small bowel
Study: NCT05287841

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Inferior Turbinate Reduction
Description: The bilateral inferior turbinates will be surgically ablated.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Inferior Turbinate Reduction
Description: The bilateral inferior turbinates will be surgically ablated.
Study: NCT04104815

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Experimental Thickener
Description: Use to thicken liquids
Study: NCT05242224

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Evolutionary Nutrition Package
Description: The evolutionary nutrition package includes two key components: 1) one full meal per day from the evolutionary nutrition (EN) plate; 2) targeted messaging for high quality nutrition and removal of ultra-processed foods from the diet. The EN plate includes five food groups identified from the literature on evolutionary diets: animal source foods (ASF); berries and other fruits; tubers; vegetables, herbs and spices; and nuts and other legumes.
Study: NCT05540561

Intervention type: OTHER
Intervention: blood collection
Description: Biological analyses in the framework of care with conservation of blood samples

Intervention type: OTHER
Intervention: blood collection
Description: Biological analyses in the framework of care with conservation of blood samples
Study: NCT05340621

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OKI-179 + binimetinib
Description: Phase 1b: With a 3+3 dose escalation design, enrollment in Phase 1b will proceed until the MTD has been defined or the highest dose level has been reached. OKI-179 will be administered on a 4-days-on/3-days-off schedule, while binimetinib will be administered BID continuously.~Phase 2: Patients will be treated with the RP2D.
Study: NCT04644237

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab deruxtecan
Description: Trastuzumab deruxtecan 100 mg will be provided as a sterile lyophilized powder and reconstituted with 5 mL water for injection (final concentration 20 mg/mL \[ie, 100 mg/5 mL\]). The study drug will be administered as an intravenous (IV) infusion over 30 to 90 min Q3W ± 2 days. The initial dose of study drug will be infused for 90 ± 10 min.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab deruxtecan
Description: Trastuzumab deruxtecan 100 mg will be provided as a sterile lyophilized powder and reconstituted with 5 mL water for injection (final concentration 20 mg/mL \[ie, 100 mg/5 mL\]). The study drug will be administered as an intravenous (IV) infusion over 30 to 90 min Q3W ± 2 days. The initial dose of study drug will be infused for 90 ± 10 min.
Study: NCT05664958

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Erector Spinae Plane (ESP) Block
Description: ESP Block with liposomal bupivacaine and immediate release bupivacaine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bupivacaine liposome injectable suspension
Description: 133 mg liposomal bupivacaine per side.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bupivacaine
Description: 20 ml bupivacaine 0.25% per side.
Study: NCT06696677

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Measuring the small instestine length using pre-marked laparoscopic graspers
Description: Intra-operatively, the surgeon will assess the length of the small intestine using a 5-cm marked laparoscopic graspers to accurately assess the whole small intestine length.
Study: NCT04309552

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 18F-FMISO PET
Description: Suspected HGG subjects will undergo combined FMISO/FLT dyn-PET at baseline as part of surgical planning. Dyn-PET images will be acquired with staggered FMISO/FLT injections using a lag time of 50 minutes. Preoperatively FMISO/FLT dyn-PET data will be used for intraoperative neuro-navigation and targeted sampling of PET avid tumor subregions prior to tumor excision. Paraffin blocks will be analyzed with immuno-histochemistry and in situ hybridization for HIF-1α, Ki-67, VEGF, EGFR, IDH, and pimonidazole, as well as TERT. FMISO-PET uptake rate, k3, (surrogate for hypoxia) and FLT-PET influx rate, Ki (surrogate for proliferation) will be correlated with time to progression, progression-free survival at 9 months, and overall survival (OS) at 1 year.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 18F-FLT PET
Description: Suspected HGG subjects will undergo combined FMISO/FLT dyn-PET at baseline as part of surgical planning. Dyn-PET images will be acquired with staggered FMISO/FLT injections using a lag time of 50 minutes. Preoperatively FMISO/FLT dyn-PET data will be used for intraoperative neuro-navigation and targeted sampling of PET avid tumor subregions prior to tumor excision. Paraffin blocks will be analyzed with immuno-histochemistry and in situ hybridization for HIF-1α, Ki-67, VEGF, EGFR, IDH, and pimonidazole, as well as TERT. FMISO-PET uptake rate, k3, (surrogate for hypoxia) and FLT-PET influx rate, Ki (surrogate for proliferation) will be correlated with time to progression, progression-free survival at 9 months, and overall survival (OS) at 1 year.
Study: NCT06697353

Intervention type: DRUG
Intervention: vericiguat (BAY 1021189)
Description: 2.5 mg initiating dose

Intervention type: DRUG
Intervention: vericiguat (BAY 1021189)
Description: 2.5 mg initiating dose

Intervention type: DRUG
Intervention: vericiguat (BAY 1021189)
Description: 2.5 mg initiating dose
Study: NCT05807139

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Spironolactone
Description: Spironolactone and its matched placebo will be encapsulated into hard gelatin capsules, in same color, size and taste, to allow blinding.~Participants will receive 2x50 mg/day, 2x100 mg, and 2x200 mg/day in three sessions (Stages); these Visits always occur in ascending order of dosage. In the remaining session, participants receive the placebo.~Spironolactone is approved by the FDA, commercially available, and used in clinical practice for the treatment of hypertension, NYHA Class III-IV heart failure, edema in cirrhotic patients, and primary hyperaldosteronism. Comprehensive information about spironolactone, including its pharmacological properties, are provided in the Prescribing Information.
Study: NCT05743556

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: HILT laserotherapy
Description: application of high intensive laser therapy on cervical muscles

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: TRT therapy
Description: application of radiofrekvention therapy on cervical muscles
Study: NCT06225375

Intervention type: DEVICE
Group type: OTHER
Intervention: Restorelle® Flat Mesh
Description: Pelvic organ prolapse repair using Restorelle® Flat Mesh
Study: NCT06697353

Intervention type: DRUG
Intervention: vericiguat (BAY 1021189)
Description: 2.5 mg initiating dose

Intervention type: DRUG
Intervention: vericiguat (BAY 1021189)
Description: 2.5 mg initiating dose
Study: NCT05195957

Intervention type: PROCEDURE
Intervention: Robotic tranversus abdominis release operation
Description: Mini-invasive robotic-assisted TAR using either DaVinci Xi or Si systems and 6 laparoscopic ports.

Intervention type: PROCEDURE
Intervention: Open transversus abdominis release operation
Description: Original open TAR using midline incision.
Study: NCT06397651

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Complement Theory's Live 1:1 Exercise Coaching and Personalized Digital Application
Description: Participants will get access to Complement Theory's 24-week Live 1:1 Coaching program, focusing on Exercise and Meditation and supplemented with evidence-based information on Diet, Sleep, and other lifestyle practices, adjunct to the core treatment.~* Each week, up to five sessions of 45 minutes each will be offered, with a recommendation for participants to engage in a minimum of three sessions to ensure adequate program exposure and benefits.~* Each session will consist of 30 Minutes of Physical Exercise and 7 minutes of meditation. Each session will be a combination session focused on Aerobic and Strength, with flexibility and balance exercises included as supplements.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Digital application with expert guidelines on lifestyle modification
Description: 24 weeks access to Digital application with expert guidelines on lifestyle modification focusing on exercise, meditation, as well as information on diet, sleep and other lifestyle practices.
Study: NCT06601517

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Repaglinide
Description: Single dose; Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atorvastatin
Description: Single dose; Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Digoxin
Description: Single dose; Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rosuvastatin
Description: Single dose; Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HDM1002
Description: Administered orally
Study: NCT04909008

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise Training
Description: 10 weeks of supervised exercise training, 3 sessions per week at the cardiac rehab clinic at Mayo Clinic Florida.
Study: NCT06605365

Intervention type: DEVICE
Intervention: CX-HA and CS
Description: Sterile Isotonic ophthalmic solution
Study: NCT06661096

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: TMJ arthroscopy
Description: level I and level II TMJ arthroscopy
Study: NCT06659328

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Structured Walking Intervention for Children with Autism Spectrum Disorder
Description: Participants: Thirty children with ASD will participate in the walking sessions.~Conditions: Each child will walk under three different speed conditions:~Normal Speed: 120 beats per minute (bpm) Slow Speed: 100 bpm Fast Speed: 140 bpm~Social Interaction: Each child will walk with two different types of adult companions:~Familiar Adult: A caregiver or individual known to the child. Unfamiliar Adult: An adult not known to the child. Procedure: The walking distance will be 10 meters. The adult will wear a metronome in an earbud to ensure that they maintain the prescribed walking speed, which the child will be instructed to follow. Each child will experience all combinations of walking speeds and social interactions, allowing for a comprehensive assessment of how these factors influence gait parameters.~Gait Parameters: The following parameters will be recorded during each walking session using video analysis software (Kinovea©):~Stride length Step time Cadence Velocity Joint amplitudes
Study: NCT04762433

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Kegel Exercise Pregnancy Training - app
Description: KEPT-app is designed to educate pregnant women on PFMT via the step-by-step training with the capability element to improve their confidence and skills (beginner, intermediate and advance skills). Pregnant women are encouraged to continue adopt the PFMT throughout pregnancy until postpartum period.~The details of the mHealth app content was developed based on the need assessment gathered from the cross-sectional study (Jaffar et al., 2020). It was conducted to identify the need of PFMT by looking at the prevalence of the UI among pregnant women and to understand their knowledge, attitude, and practices towards PFMT.
Study: NCT06697353

Intervention type: DRUG
Intervention: vericiguat (BAY 1021189)
Description: 2.5 mg initiating dose

Intervention type: DRUG
Intervention: vericiguat (BAY 1021189)
Description: 2.5 mg initiating dose

Intervention type: DRUG
Intervention: vericiguat (BAY 1021189)
Description: 2.5 mg initiating dose

Intervention type: DRUG
Intervention: vericiguat (BAY 1021189)
Description: 2.5 mg initiating dose

Intervention type: DRUG
Intervention: vericiguat (BAY 1021189)
Description: 2.5 mg initiating dose

Intervention type: DRUG
Intervention: vericiguat (BAY 1021189)
Description: 2.5 mg initiating dose

Intervention type: DRUG
Intervention: vericiguat (BAY 1021189)
Description: 2.5 mg initiating dose

Intervention type: DRUG
Intervention: vericiguat (BAY 1021189)
Description: 2.5 mg initiating dose

Intervention type: DRUG
Intervention: vericiguat (BAY 1021189)
Description: 2.5 mg initiating dose

Intervention type: DRUG
Intervention: vericiguat (BAY 1021189)
Description: 2.5 mg initiating dose
Study: NCT05795231

Intervention type: DEVICE
Intervention: Macintosh Laryngoscope Vs Video Laryngoscope
Description: Evaluate incidence of first trial success and complications

Intervention type: DEVICE
Intervention: Macintosh Laryngoscope Vs Video Laryngoscope
Description: Evaluate incidence of first trial success and complications